TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2022
|
|
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 20, 2022
|
|
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
Apr 26, 2022
|
|
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
Apr 15, 2022
|
|
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Apr 06, 2022
|
|
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
Apr 04, 2022
|
|
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
Mar 10, 2022
|
|
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Mar 04, 2022
|
|
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
Mar 03, 2022
|
|
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
Mar 01, 2022
|
|